RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group.
SourceEuropean Journal of Cancer, 40, 9, (2004), pp. 1332-4
Article / Letter to editor
Display more detailsDisplay less details
European Journal of Cancer
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.